RxDoctor Payments DataLook up a doctor →

Mark Allen Ramirez, MD

Neurology · Roseburg, ORNPI 1245400209

Payments from drug & device makers

$14,182in general payments, 2019–2025

Across 716 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lundbeck LLC$1K
  • Neurocrine Biosciences, Inc.$949
  • Teva Pharmaceuticals USA, Inc.$860
  • Sunovion Pharmaceuticals Inc.$754
  • UCB, Inc.$726
  • plus $7K from 46 others

What the payments were for

  • Speaking & faculty fees$801%
  • Food & beverage$13,79397%
  • Education$3092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,182 in reported general payments places this provider in the 75th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$221,050
Medicare patients
393
Services billed
17,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe102$73,574
Ajovy AutoinjectorFremanezumab-Vfrm38$40,264
Emgality PenGalcanezumab-Gnlm41$33,804
UbrelvyUbrogepant33$32,801
Nurtec OdtRimegepant Sulfate26$27,130
NeuproRotigotine14$16,718
QuliptaAtogepant14$14,640
Topiramate ErTopiramate12$14,136
Rasagiline Mesylate31$7,020
Repatha SureclickEvolocumab12$6,452
Tegretol XrCarbamazepine13$5,696
Lacosamide23$5,201
Carbidopa-LevodopaCarbidopa/Levodopa75$4,230
Sumatriptan Succinate60$3,761
Levetiracetam112$3,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,675$47,44047 claims
PfizerNurtec Odt$556$27,13026 claims
UCB, Inc.Neupro$726$16,71814 claims
Upsher-smith Laboratories LLCTopiramate$460$2,961230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 228 neurology providers in Oregon.

Other neurology in Roseburg

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →